Literature DB >> 25413642

Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort.

E Jennifer Edelman1, Debbie M Cheng, Evgeny M Krupitsky, Carly Bridden, Emily Quinn, Alexander Y Walley, Dmitry A Lioznov, Elena Blokhina, Edwin Zvartau, Jeffrey H Samet.   

Abstract

Opioids have immunosuppressive properties, yet their impact on HIV disease progression remains unclear. Using longitudinal data from HIV-infected antiretroviral therapy-naïve Russian individuals (n = 77), we conducted a pilot study to estimate the effect of heroin use on HIV disease progression. Heroin use was categorized based on past 30 days self-reported use at baseline, 6 and 12 months as none, intermittent or persistent. We estimated the effect of heroin use on HIV disease progression, measured as change in CD4 count from baseline to 12 months, using multivariable linear regression. Those with intermittent (n = 21) and no heroin use (n = 39) experienced mean decreases in CD4 count from baseline to 12 months (-103 and -10 cells/mm(3), respectively; adjusted mean difference (AMD) -93; 95 % CI -245, 58). Those with persistent use (n = 17) showed a mean increase of 53 cells/mm(3) (AMD 63; 95 % CI -95, 220). Future studies exploring the effects of heroin withdrawal on HIV disease progression are warranted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25413642      PMCID: PMC4440848          DOI: 10.1007/s10461-014-0948-z

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  51 in total

1.  Alcohol use accelerates HIV disease progression.

Authors:  Marianna K Baum; Carlin Rafie; Shenghan Lai; Sabrina Sales; John Bryan Page; Adriana Campa
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

Review 2.  Cannabinoid neuroimmune modulation of SIV disease.

Authors:  Patricia E Molina; Angela Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter Winsauer; Curtis Vande Stouwe
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-10       Impact factor: 4.147

3.  Non-analgesic effects of opioids: mechanisms and potential clinical relevance of opioid-induced immunodepression.

Authors:  Paola Sacerdote; Silvia Franchi; Alberto E Panerai
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users.

Authors:  Thomas Kerr; Brandon D L Marshall; M-J Milloy; Ruth Zhang; Silvia Guillemi; Julio S G Montaner; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2012-01-14       Impact factor: 4.492

5.  Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.

Authors:  Aaron M Kipp; Andrew J Desruisseau; Han-Zhu Qian
Journal:  J Subst Abuse Treat       Date:  2011-02-24

Review 6.  Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections.

Authors:  Sabita Roy; Jana Ninkovic; Santanu Banerjee; Richard Gene Charboneau; Subhas Das; Raini Dutta; Varvara A Kirchner; Lisa Koodie; Jing Ma; Jingjing Meng; Roderick A Barke
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-26       Impact factor: 4.147

7.  The onset of HIV infection in the Leningrad region of Russia: a focus on drug and alcohol dependence.

Authors:  E Krupitsky; E Zvartau; G Karandashova; N J Horton; K R Schoolwerth; K Bryant; J H Samet
Journal:  HIV Med       Date:  2004-01       Impact factor: 3.180

8.  Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.

Authors:  Richard D Moore; Jeanne C Keruly; Richard E Chaisson
Journal:  J Acquir Immune Defic Syndr       Date:  2004-01-01       Impact factor: 3.731

Review 9.  Breaking worse: the emergence of krokodil and excessive injuries among people who inject drugs in Eurasia.

Authors:  Jean-Paul C Grund; Alisher Latypov; Magdalena Harris
Journal:  Int J Drug Policy       Date:  2013-05-31

10.  Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts.

Authors:  Catherine C McGowan; David D Weinstein; Charles P Samenow; Samuel E Stinnette; Gema Barkanic; Peter F Rebeiro; Timothy R Sterling; Richard D Moore; Todd Hulgan
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240

View more
  8 in total

Review 1.  Behavioral Interventions Targeting Alcohol Use Among People Living with HIV/AIDS: A Systematic Review and Meta-Analysis.

Authors:  Lori A J Scott-Sheldon; Kate B Carey; Blair T Johnson; Michael P Carey
Journal:  AIDS Behav       Date:  2017-11

Review 2.  HIV, Tat and dopamine transmission.

Authors:  Peter J Gaskill; Douglas R Miller; Joyonna Gamble-George; Hideaki Yano; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2017-04-27       Impact factor: 5.996

3.  The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy.

Authors:  E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin
Journal:  HIV Med       Date:  2016-11       Impact factor: 3.180

4.  Impact of illicit opioid use on T cell subsets among HIV-infected adults.

Authors:  E Jennifer Edelman; Kaku So-Armah; Debbie M Cheng; Margaret F Doyle; Sharon M Coleman; Carly Bridden; Natalia Gnatienko; Dmitry A Lioznov; Elena Blokhina; Matthew S Freiberg; Evgeny M Krupitsky; Brinda Emu; Jeffrey H Samet
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

5.  Rates and risk factors associated with the progression of HIV to AIDS among HIV patients from Zhejiang, China between 2008 and 2012.

Authors:  Lin Chen; Jiezhe Yang; Renjie Zhang; Yun Xu; Jinlei Zheng; Jianmin Jiang; Jun Jiang; Lin He; Ning Wang; Philip Chun Yeung; Xiaohong Pan
Journal:  AIDS Res Ther       Date:  2015-09-25       Impact factor: 2.250

6.  Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users.

Authors:  Eric M Ndombi; Valentine Budambula; Mark K Webale; Francis O Musumba; Jesca O Wesongah; Erick Mibei; Aabid A Ahmed; Raphael Lihana; Tom Were
Journal:  Endocr Connect       Date:  2015-08-25       Impact factor: 3.335

7.  Role of substance use in HIV care cascade outcomes among people who inject drugs in Russia.

Authors:  Bulat Idrisov; Karsten Lunze; Debbie M Cheng; Elena Blokhina; Natalia Gnatienko; Emily Quinn; Carly Bridden; Alexander Y Walley; Kendall J Bryant; Dmitry Lioznov; Evgeny Krupitsky; Jeffrey H Samet
Journal:  Addict Sci Clin Pract       Date:  2017-12-04

8.  Escalating morphine dosing in HIV-1 Tat transgenic mice with sustained Tat exposure reveals an allostatic shift in neuroinflammatory regulation accompanied by increased neuroprotective non-endocannabinoid lipid signaling molecules and amino acids.

Authors:  Douglas J Hermes; Ian R Jacobs; Megan C Key; Alexis F League; Barkha J Yadav-Samudrala; Changqing Xu; Virginia D McLane; Sara R Nass; Wei Jiang; Rick B Meeker; Bogna M Ignatowska-Jankowska; Aron H Lichtman; Zibo Li; Zhanhong Wu; Hong Yuan; Pamela E Knapp; Kurt F Hauser; Sylvia Fitting
Journal:  J Neuroinflammation       Date:  2020-11-18       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.